行情

CYAD

CYAD

Celyad Oncology
NASDAQ

实时行情|Nasdaq Last Sale

5.47
-0.01
-0.18%
交易中 10:59 06/16 EDT
开盘
5.52
昨收
5.48
最高
5.52
最低
5.46
成交量
2.49万
成交额
--
52周最高
12.44
52周最低
5.25
市值
7,626.46万
市盈率(TTM)
-3.6295
分时
5日
1月
3月
1年
5年
Celyad Oncology 股价飙升至交易日高点,继美国专利商标局针对 Co. 的“用于提高细胞持久性以进行过继转移的组合物和方法”摘要后,股价飙升至高点,并创下新低
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20210171907&OS=20210171907&RS=20210
Benzinga · 4天前
BRIEF-Celyad Oncology: Preliminary Data From IMMUNICY-1 trial of CYAD-211
reuters.com · 5天前
生物技术的未来一周:Biogen、Alexion 和 Vertex FDA 的决定,甲板上的多个会议演示
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week, headlining the biotech news flow of the week.
Benzinga · 06/07 12:52
12 只医疗保健股在周一的盘前交易时段内移动
 
Benzinga · 06/07 12:07
22 只股票在周一的盘前交易时段内波动
Gainers Liminal BioSciences Inc. (NASDAQ: LMNL) rose 51.7% to $6.10 in pre-market trading. Liminal BioSciences reported the FDA approval for its Biologics License Application for Ryplazim.
Benzinga · 06/07 11:04
昨天的77大动作
Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped 23.6% to close at $9.52.
Benzinga · 05/14 09:19
周四午盘交易中的44只股票
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) jumped 38.7% to $4.0901 after the company said it has acquired a premier health insurance agency, J.P. Kush and Associates, Inc.
Benzinga · 05/13 16:05
每日生物技术脉动:默克公司报告乳腺癌,Curis,收入诱发低落的阳性Keytruda数据,Qiagen的快速COVID-19抗体快速测试可以用于紧急情况
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 05/13 12:10
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CYAD最新的财务预测,通过CYAD每股收益,每股净资产,每股现金流等数据分析Celyad Oncology近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CYAD价格均价为18.42,最高价位19.92,最低价为16.93。
EPS
机构持股
总机构数: 12
机构持股: 78.20万
持股比例: 5.61%
总股本: 1,394.23万
类型机构数股数
增持
1
1,392
建仓
0
0
减持
3
4.93万
平仓
1
53
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.10%
制药与医学研究
+0.34%
高管信息
Chairman/Co-Founder/Director
Michel Lussier
Chief Executive Officer/Executive Director/Executive Board
Christian Homsy
Chief Financial Officer/Executive Board/Primary Contact
Patrick Jeanmart
Chief Operating Officer
Gaetane Metz
Vice President
Richard Mountfield
Vice President - Research & Development/Executive Board
Peter De Waele
Vice President - Business Development
Georges Rawadi
Other
Seron Aymeric
Other
Philippe Dechamps
Other
Roland Gordon-Beresford
Non-Executive Director
Serge Goblet
Non-Executive Director
Hanspeter Spek
Non-Executive Director
William Wijns
Independent Director
Chris Buyse
Independent Director
Rudy Dekeyser
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
暂无数据
CYAD 简况
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

微牛提供Celyad Oncology SA(NASDAQ-CYAD)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CYAD股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CYAD股票基本功能。